Get the Stockscreener App
1.6753
4.29%
-0.0747
Enveric Biosciences Inc stock is traded at $1.6753, with a volume of 128.87K.
It is down -4.29% in the last 24 hours and down -41.23% over the past month.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
See More
Previous Close:
$1.75
Open:
$1.73
24h Volume:
128.87K
Relative Volume:
0.04
Market Cap:
$6.15M
Revenue:
-
Net Income/Loss:
$-8.22M
P/E Ratio:
-0.0613
EPS:
-27.3467
Net Cash Flow:
$-8.01M
1W Performance:
-24.55%
1M Performance:
-41.23%
6M Performance:
-71.71%
1Y Performance:
-89.26%
1-Day Range:
$1.6501
$1.81
1-Week Range:
$1.6501
$2.25
52-Week Range:
$1.6501
$17.64
Enveric Biosciences Inc Stock (ENVB) Company Profile
Name
Enveric Biosciences Inc
Sector
Industry
Phone
(617) 444-8400
Address
245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE
Compare ENVB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
1.67 | 6.44M | 0 | -8.22M | -8.01M | -27.35 |
VRTX
Vertex Pharmaceuticals Inc
|
447.52 | 112.43B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
616.68 | 64.09B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
880.71 | 54.88B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.11 | 39.01B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
148.85 | 31.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enveric Biosciences Inc Stock (ENVB) Latest News
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day - Investing News Network
Enveric Biosciences posts investor presentation on website under Regulation FD - TradingView
Enveric Biosciences (NASDAQ: ENVB) furnishes Q2 2026 investor presentation - Stock Titan
ENVB Stock Chart | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
[Form 4] Enveric Biosciences, Inc. Insider Trading Activity - Stock Titan
Enveric Biosciences (ENVB) CFO awarded 133,333 RSUs in long-term equity grant - Stock Titan
Enveric Biosciences (ENVB) CEO granted 201,124 RSUs under 2020 long-term plan - Stock Titan
Enveric Biosciences (ENVB) director receives 18,518 restricted stock shares as equity grant - Stock Titan
Director at Enveric Biosciences (ENVB) receives 18,518 restricted shares - Stock Titan
Enveric (ENVB) awards director Marcus Schabacker 18,518 restricted shares - Stock Titan
Enveric Biosciences (ENVB) awards 25,000 RSUs to its CIO - Stock Titan
Enveric Biosciences (ENVB) Launches Critical Safety Studies for EB-003 - GuruFocus
Enveric Biosciences Initiates Investigational New Drug -enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 - Investing News Network
Enveric Biosciences stock rises on genotoxicity study launch By Investing.com - Investing.com India
Enveric Biosciences stock rises on genotoxicity study launch - Investing.com
Enveric Biosciences begins genotoxicity studies for EB-003 - Investing.com
Enveric Biosciences begins genotoxicity studies for EB-003 By Investing.com - Investing.com Canada
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 - Business Wire
Enveric Biosciences (NASDAQ: ENVB) holders OK reverse split, block share increase - Stock Titan
Enveric Biosciences Holds Near Support Amid Modest PullbackPCR Moving Average - thelegaladvocate.com
ENVB Technical Analysis | Trend, Signals & Chart Patterns | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
Enveric Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
ENVB Stock Price, Quote & Chart | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
Enveric Biosciences Company Profile & Introduction - Moomoo
Enveric Biosciences Inc. (ENVB) Q4 2024 Earnings: Massive EPS Miss Highlights Ongoing Cash Burn and No Revenue - thelegaladvocate.com
Enveric Biosciences (ENVB) Achieves Key Milestone in Neuropsychi - GuruFocus
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 - Investing News Network
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 - BioSpace
Enveric Biosciences 1Q Loss/Shr $1.08 >ENVB - Moomoo
Enveric Biosciences Inc (ENVB) Stock Price, Quote, News & History - Benzinga
Enveric Biosciences (ENVB) affiliates report 158,732 warrants; Easton 161,232 - Stock Titan
Enveric (ENVB) Secures $13.9 Million in Private Placement Fundin - GuruFocus
Enveric (ENVB) Advances in Mental Health Therapeutics Developmen - GuruFocus
Enveric Biosciences Reports Q1 2026 Results, Advances Non-Hallucinogenic Antidepressant EB-003 Toward Clinical Trials - Minichart
Enveric Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Enveric Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Enveric Biosciences (NASDAQ: ENVB) posts Q1 2026 loss and flags going concern risk - Stock Titan
Enveric Biosciences (ENVB) advances EB-003 and boosts cash in Q1 2026 - Stock Titan
What's going on with Enveric Biosciences stock on Friday? - MSN
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders - Investing News Network
Enveric highlights preclinical PTSD data amid rising focus on mental health therapies - MSN
Enveric Biosciences receives patent for psilocybin derivatives By Investing.com - Investing.com Canada
Enveric Biosciences Stock Short Interest Rises to 45.7% - Moomoo
TradingKey - TradingKey
MSN Money - MSN
Enveric Biosciences Inc Stock (ENVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.62%
1.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):